PubMed COVID-19 Clinical Care

CONCLUSIONS: The BSID-IV is widely used to assess for developmental delays in the high-risk infant population, but in-person administration of this tool poses limitations on its accessibility. Telehealth administration of an alternative tool, such as

CONCLUSIONS: The BSID-IV is widely used to assess for developmental delays in the high-risk infant population, but in-person administration of this tool poses limitations on its accessibility. Telehealth administration of an alternative tool, such as

CONCLUSIONS: The BSID-IV is widely used to assess for developmental delays in the high-risk infant population, but in-person administration of this tool poses limitations on its accessibility. Telehealth administration of an alternative tool, such as

No abstract

This open-label, extension study assessed long-term safety, tolerability, and efficacy of ambrisentan in a pediatric population (age 8- 18 years) with pulmonary arterial hypertension (PAH). Following completion of a 6-month, randomized study

Given the increasing effectiveness of immune-based therapies, management of their associated toxicities is of utmost importance. Cytokine release syndrome (CRS), characterized by elevated levels of cytokine, poses a significant challenge following

CONCLUSIONS: Having constructed a (hit) severity measure that enables to differentiate between countries' performances in a sound way, further research should now relate these observed differences to the pre-pandemic health care status and the

The coronavirus outbreak caused most education institutions to shift to online education. One of the consequences of the pandemic and spread of online education was the prevalence of academic burnout among students has been students' academic burnout

CONCLUSIONS: Results suggest that the vast majority of the dental care professionals in Indonesia had adequate knowledge and awareness of COVID-19. However, some aspects of practice need to be improved in IC and related aspects.

Antivirals with proven effectiveness against the Omicron SARS-CoV-2 variant are required for COVID-19 treatment in hospitalized patients, particularly those with severe underlying conditions. Ensitrelvir, a 3C-like protease inhibitor, received